USE OF LINEZOLID IN THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS
Abstract
Introduction: Tuberculosis is a relatively simple and inexpensive disease to diagnose, in most cases, it can be cured with well-tolerated, effective, and low-cost treatments. However, multidrug-resistant tuberculosis remains a major challenge. The study aims to evaluate the level of effectiveness of linezolid in the treatment of multidrug-resistant tuberculosis. Methods: This is an integrative review, in which the guiding question was "Is linezolid effective in the treatment of multidrug-resistant tuberculosis?". The search for articles occurred in the main databases (PubMed, Scielo, and Google Scholar) using the terms "tuberculosis," "linezolid" and "drug-resistant" combined with Boolean operators.
Results and discussion: linezolid, both as a substitute for drugs in traditional therapy and in addition to new treatments for multidrug-resistant tuberculosis, has been shown to lead to positive outcomes. However, the dose should be individualized to each patient, due to the occurrence of adverse effects, mainly peripheral neuropathy, and myelosuppression.
Conclusion: the use of linezolid in the treatment of multidrug-resistant tuberculosis effectively reduces the time of drug intervention and, especially, in resolving the pathological picture. However, a cautious analysis of the administered dose should be performed since the medication has shown a high occurrence of adverse events.
Author Biographies
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Centro Universitário Claretiano.
Universidade José do Rosário Vellano - UNIFENAS.
References
Rojano B, Caminero JA, Hayek M. Curving Tuberculosis: Current Trends and Future Needs. Ann Glob Health. 2019 Jan 22;85(1):5. PMID: 30741506; PMCID: PMC7052330 DOI: https://doi.org/10.5334/aogh.2415
Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harb Perspect Med. 2015 Apr 27;5(9):a017863. PMID: 25918181; PMCID: PMC4561400 DOI: https://doi.org/10.1101/cshperspect.a017863
Dean AS, Tosas Auguet O, Glaziou P, Zignol M, Ismail N, Kasaeva T, Floyd K. 25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward. Lancet Infect Dis. 2022 Jul;22(7):e191-e196. Epub 2022 Mar 3. PMID: 35248168; PMCID: PMC8893725 DOI: https://doi.org/10.1016/S1473-3099(21)00808-2
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M; ZeNix Trial Team. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 Sep 1;387(9):810-823. PMID: 36053506; PMCID: PMC9490302 DOI: https://doi.org/10.1056/NEJMoa2119430
Silva, M. E. da, Silva, W. M. da, Silva, G. M. da, Souza, R. G. de, Santos, J. A. dos, Luz, M. K. S. da, Ferreira, M. D. F., Silva, T. M. L., Rocha, L. C. P. da, & Silva, C. A. de O. (2020). Manifestações neurológicas provocadas por COVID-19: uma revisão integrativa da literatura / Neurological manifestations caused by COVID-19: an integrative literature review. Brazilian Journal of Development, 6(7), 52155–52163. https://doi.org/10.34117/bjdv6n7-750
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008.
Sousa, Luís & Marques-Vieira, Cristina & Severino, Sandy & Antunes, Vanessa. (2017). Metodologia de Revisão Integrativa da Literatura em Enfermagem. Revista Investigação Enfermagem. 2. 17-26.
Abdelwahab, M. T., Wasserman, S., Brust, J. C. M., Dheda, K., Wiesner, L., Gandhi, N. R., Warren, R. M., Sirgel, F. A., Meintjes, G., Maartens, G., & Denti, P. (2021). Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy, 65(12), e0138121. https://doi.org/10.1128/AAC.01381-21
Lee, J. K., Lee, J. Y., Kim, D. K., Yoon, H. I., Jeong, I., Heo, E. Y., Park, Y. S., Jo, Y. S., Lee, J. H., Park, S. S., Park, J. S., Kim, J., Lee, S. M., Joh, J. S., Lee, C. H., Lee, J., Choi, S. M., Park, J. H., Lee, S. H., Cho, Y. J., … Yim, J. J. (2019). Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. The Lancet. Infectious diseases, 19(1), 46–55. https://doi.org/10.1016/S1473-3099(18)30480-8
Qiao, J., Yang, L., Feng, J., Dai, X., Xu, F., & Xia, P. (2022). Analysis of efficacy and safety of linezolid-based chemotherapeutic regimens for patients with postoperative multidrug-resistant spinal tuberculosis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 118, 264–269. https://doi.org/10.1016/j.ijid.2022.03.020
Mok, J., Lee, M., Kim, D. K., Kim, J. S., Jhun, B. W., Jo, K. W., Jeon, D., Lee, T., Lee, J. Y., Park, J. S., Lee, S. H., Kang, Y. A., Lee, J. K., Kwak, N., Ahn, J. H., Shim, T. S., Kim, S. Y., Kim, S., Kim, K., Seok, K. H., … MDR-END investigators (2022). 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet (London, England), 400(10362), 1522–1530. https://doi.org/10.1016/S0140-6736(22)01883-9
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., McHugh, T. D., Wills, G. H., Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., Spigelman, M., & Nix-TB Trial Team (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine, 382(10), 893–902. https://doi.org/10.1056/NEJMoa1901814
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.